Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1Osteoarthritis 1Low Back Pain 1Leukemia, Myeloid, Acute 1Cancer Pain 1

Interventions

Morphine 15Oxycodone 13Fentanyl 9nabiximols 5Methadone 5Lidocaine 5Acetaminophen 5resiniferatoxin 4Ethanol 4Acupuncture Therapy 4Transcutaneous Electric Nerve Stimulation 3Hydromorphone 3Transcranial Direct Current Stimulation 2Surveys and Questionnaires 2Standard of Care 2Sodium Bicarbonate 2Radiofrequency Ablation 2Pharmaceutical Services 2Naloxone 2Ketamine 2Electroacupuncture 2Dronabinol 2Control Groups 2Buprenorphine 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1rofecoxib 1naloxegol 1incobotulinumtoxinA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cancer Pain × Inosine Monophosphate × Clear all
NCT03031938 2021-06-25

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Pfizer

Phase 3 Completed
4 enrolled 78 charts

Cancer Pain, Osteoarthritis, Low Back Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡